Related Experiment Videos
Potent inhibition of CTLA-4 expression by an anti-CTLA-4 ribozyme
E Cepero1, H J Hnatyszyn, G Kraus
1Department of Microbiology and Immunology, University of Miami, School of Medicine, Florida 33101, USA.
Abstract:
Blockading the negative-regulatory CTLA-4 receptor has emerged as a powerful strategy with clinical potential to enhance T-cell responses. Some experimental tumors, for example, are rejected when anti-CTLA-4 antibodies are administered in vivo. The concise target cells and downstream events, however, remain to be defined. The development of gene transfer reagents that inhibit CTLA-4 may facilitate such investigations and may expand the therapeutic range. This communication describes an anti-CTLA-4 hairpin ribozyme that specifically abrogates CTLA-4 expression after gene transfer into a murine T-cell model. The analysis of multiple and independently derived clones and bulk cultures showed that CTLA-4 induction was inhibited > 90% at the RNA level and that it was undetectable at the protein level, with and without selective pressure. This potent inhibition required the catalytic function of the ribozyme. The anti-CTLA-4 ribozyme may be an alternative tool with which to continue the functional and therapeutical exploration of CTLA-4.
Insights
Researchers developed a novel anti-CTLA-4 ribozyme to block CTLA-4 expression in T-cells. This gene transfer tool effectively inhibits CTLA-4 at both RNA and protein levels, aiding further research into its therapeutic potential.
Area of Science:
- Immunology
- Molecular Biology
- Gene Therapy
Background:
- Blockading the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) receptor enhances T-cell responses and has clinical potential.
- Anti-CTLA-4 antibodies can reject experimental tumors, but target cells and downstream events require further definition.
- Gene transfer reagents inhibiting CTLA-4 are needed for detailed investigation and therapeutic expansion.
Purpose of the Study:
- To describe a novel anti-CTLA-4 hairpin ribozyme for gene transfer.
- To assess the efficacy of this ribozyme in abrogating CTLA-4 expression in a murine T-cell model.
Main Methods:
- Development of an anti-CTLA-4 hairpin ribozyme.
- Gene transfer into a murine T-cell model.
- Analysis of CTLA-4 expression at RNA and protein levels using multiple clones and bulk cultures.
- Assessment of ribozyme catalytic function requirement.
Main Results:
- The anti-CTLA-4 ribozyme specifically abrogated CTLA-4 expression after gene transfer.
- CTLA-4 induction was inhibited by over 90% at the RNA level.
- CTLA-4 protein expression was undetectable, irrespective of selective pressure.
- The observed potent inhibition was dependent on the ribozyme's catalytic activity.
Conclusions:
- The developed anti-CTLA-4 ribozyme is a potent tool for inhibiting CTLA-4 expression.
- This ribozyme facilitates functional and therapeutic exploration of CTLA-4.
- It offers an alternative strategy to antibodies for investigating CTLA-4's role in T-cell responses.